4basebio PLC
4BB.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £158,710 | £83,771 | £87,454 | £75,752 |
| - Cash | £34,604 | £3,069 | £4,351 | £9,586 |
| + Debt | £15,216 | £10,457 | £3,350 | £1,758 |
| Enterprise Value | £139,322 | £91,159 | £86,453 | £67,924 |
| Revenue | £933 | £506 | £268 | £338 |
| % Growth | 84.4% | 88.8% | -20.7% | – |
| Gross Profit | £630 | £340 | £239 | £269 |
| % Margin | 67.5% | 67.2% | 89.2% | 79.6% |
| EBITDA | -£10,969 | -£7,343 | -£5,409 | -£3,207 |
| % Margin | -1,175.7% | -1,451.2% | -2,018.3% | -948.8% |
| Net Income | -£12,333 | -£7,665 | -£5,150 | -£3,235 |
| % Margin | -1,321.9% | -1,514.8% | -1,921.6% | -957.1% |
| EPS Diluted | -0.94 | -0.62 | -0.42 | -0.26 |
| % Growth | -51.6% | -47.6% | -61.5% | – |
| Operating Cash Flow | -£10,744 | -£6,178 | -£4,704 | -£2,740 |
| Capital Expenditures | -£1,571 | -£1,490 | -£1,941 | -£1,512 |
| Free Cash Flow | -£12,315 | -£7,668 | -£6,645 | -£4,252 |